Introduction {#s1}
============

Hypertension is a major global health issue due to its high prevalence, under-treatment, and significant cardiovascular complications \[[@R01], [@R02]\].The eighth Joint National Committee (JNC 8) guidelines recommend thiazide-type diuretics as first-line antihypertensive agents for all ethnicities \[[@R02]\]. Because they are effective, inexpensive, and relatively safe medications with long track records, thiazides are among the widely prescribed antihypertensive medications worldwide \[[@R03], [@R04]\]. In 2001 - 2010, 22.4-27.6% of patients with hypertension in the USA were prescribed with thiazide diuretics or thiazide-combination medications \[[@R05]\].

Skin cancer is the most common malignancy in the USA and it was estimated that one in five Americans will develop skin cancer in their lifetime \[[@R06]-[@R08]\]. Notably, some reported thiazides to be photosensitizing agents that may trigger an abnormal skin response to ultraviolet (UV) light \[[@R9], [@R10]\]. This response is mediated by UV-induced dissociation of chlorine substituent of thiazides which causes free radical reaction and the formation of reactive oxygen species (ROS) \[[@R11]-[@R13]\]. Studies have shown that drug-induced photosensitization of the skin and subsequent exposure to UV radiation increased the risk of skin cancers \[[@R14]-[@R16]\].Therefore, there is a concern that the use of thiazide diuretics may increase the risk of skin cancers \[[@R03]\]. Although several observational studies have investigated the association between thiazide medication use and skin cancers \[[@R17]-[@R27]\], the results are conflicting, and the exact relationship remains controversial. Therefore, we performed a meta-analysis of observational studies to investigate the association between the use of thiazides and the risk of skin cancers.

Materials and Methods {#s2}
=====================

Search strategy {#s2a}
---------------

This study was conducted according to the Meta-analyses Of Observational Studies in Epidemiology (MOOSE) guideline \[[@R28]\]. The MOOSE checklist is available in supporting information (Supplementary [Table 1](#T1){ref-type="table"}). PubMed, EMBASE, and the Cochrane Library were searched from their inception, respectively, until October 30, 2017. We used common keywords related to thiazide diuretics and skin cancers, including basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and malignant melanoma (MM), without language restriction. The detailed search terms are described in supporting information (Supplementary Method). We also reviewed the bibliographies of relevant articles to locate additional publications. Only studies published in journals were considered to be included.

###### Characteristics of Studies Included in the Final Analysis of Thiazide Diuretics and Skin Cancer

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study             Country                 Study design   Medication            Outcome   Study population (case group or cohort)           Exposed/ unexposed                                RR or OR (95% CI)    Adjusted RR or OR (95% CI)   Study period (year)   Adjustment
  ----------------- ----------------------- -------------- --------------------- --------- ------------------------------------------------- ------------------------------------------------- -------------------- ---------------------------- --------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Pottegard 2017    Denmark                 Case-control   HCTZ                  SCC       Mean age 72, men 67.3%                            Cases: 139/494, controls:7,401/55,666             2.2 (1.8 - 2.6)      2.1 (1.7 - 2.6)              2004 - 2012           Adjusted for age, gender, calendar time, use of topical retinoids, oral retinoids, tetracycline, macrolides, aminoquinolines, amiodarone, aspirin, non-aspirin non-steroidal anti-inflammatory drugs, statins, history of heavy alcohol consumption, diabetes, or chronic obstructive pulmonary disease, non-melanoma skin cancer, Charlson Comorbidity Index score, and highest achieved education

  Nardone 2017      USA                     Cohort         Thiazides             BCC       Age 18 - 89, men 37.5%, white 34%                 Cases: 262/457, controls: 15,166/45,498           1.73 (1.49 - 2.02)   2.11 (1.60 - 2.79)           2004 - 2014           Matched for age and time to follow-up, and adjusted for age, gender, race, and the Charlson Comorbidities Index

                                                                                 SCC                                                         Cases: 130/132, controls: 15,166/45,498           2.97 (2.33 - 3.79)   4.11 (2.66 - 6.35)                                 

                                                                                 MM                                                          Cases: 99/145, controls:15,166/45,498             2.06 (1.59 - 2.66)   1.82 (1.01 - 3.82)                                 

  Schmidt 2015      Denmark                 Case-control   Thiazides             BCC       Median age 67, men 50%                            Cases: 2,710/10,473, controls: 26,504/107,016     NA                   1.05 (1.00 - 1.11)           1991 - 2010           Matched for birth year, sex and county of residence, and adjusted for Charlson Comorbidity Index score, hospital-diagnosed obesity and use of systemic glucocorticoids, aspirin, non-aspirin non-steroidal, anti-inflammatory drugs and statins

                                                                                 SCC       Median age 77, men 63%                            Cases: 447/1,135, controls: 4,458/12,007          NA                   1.03 (0.91 - 1.17)                                 

                                                                                 MM        Median age 58, men 46%                            Cases: 403/2,648, controls: 3,786/26,686          NA                   1.11 (0.97 - 1.25)                                 

  Robinson 2013     USA                     Case-control   HCTZ or combination   SCC       Age 25 - 74, men 61.7%                            Cases: 1,599 in total, controls: 1,906 in total   NA                   1.3 (0.7 - 2.4)              1993 - 2009           Matched for age and sex, and adjusted for age, sex, and number of previous painful sunburns

  de Vries 2012     Europe (multi-center)   Case-control   Thiazides             BCC       Median age 72, men 59.6%                          Case: 94/508, control: 136/1,414                  1.92 (NA)            1.27 (0.92 - 1.75)           NA                    Matched for age and sex, and adjusted for age, sex, skin photo-type and country

                                                                                 SCC       Median age 76, men 70.2%                          Case: 99/310, control: 136/1,414                  3.32 (NA)            1.66 (1.16 - 2.37)                                 

                                                                                 MM        Median age 62, men 54.4%                          Cases: 33/327, control: 136/1,414                 1.05 (NA)            1.22 (0.77 - 1.93)                                 

  Friedman 2012     USA                     Case-control   HCTZ or\              SCC       Mean age 68, men 74.4%, non-Hispanic white 100%   Cases: 103/609, controls: 1,896/21,008            2.22 (1.76 - 2.79)   2.19 (1.74 - 2.76)           1994 - 2008           Matched for age, sex, and year of entry into the cohort, and adjusted for smoking
                                                           combination                                                                                                                                                                                                 

  Ruiter 2010       Netherlands             Cohort         Thiazides             BCC       Mean age 69, men 40%                              137/385                                           NA                   1.00 (0.95 - 1.05)           1991 - 2007           Adjusted for age and gender, and none of the potential covariates was a confounder

  Jensen 2008       Denmark                 Case-control   HCTZ                  BCC       Mean age 69                                       Cases: 542/5,422, controls: 2,059/21,797          NA                   1.05 (0.95 - 1.16)           1989 - 2003           Matched for age and sex, and adjusted for prior hospitalization for selected chronic diseases and use of glucocorticoids

                                                                                 SCC       Mean age 77                                       Cases: 159/910, controls: 427/4,089               NA                   1.58 (1.29 - 1.93)                                 

                                                                                 MM        Mean age 59                                       Cases: 98/912, controls: 303/3,737                NA                   1.32 (1.03 - 1.70)                                 

  Westerdahl 1996   Sweden                  Case-control   Thiazide              MM        Age 15 - 75, men 46.6%                            Cases: 20/328, controls: 25/535                   1.4 (0.7 - 2.7)      1.4 (0.7 - 2.8)              1988 - 1990           Matched for sex, age, parish, and adjusted for history of sunburns and host factors (hair color, number of raised naevi)
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

BCC: basal cell carcinoma; SCC: squamous cell carcinoma; MM: malignant melanoma; HCTZ: hydrochlorothiazide; RR: risk ratio; OR: odds ratio; CI: confidence interval; NA: not available; USA: United States of America.

Study selection {#s2b}
---------------

Observational studies that met all of the following criteria were included: 1) Those that were case-control or cohort studies (no randomized controlled trials have been published to date); 2) Those that investigated the association between the use of any type of thiazides or thiazide combination medications for hypertension and the risk of skin cancers; and 3) Those that reported outcome measures with adjusted relative risk (aRR) or adjusted odds ratio (aOR) and 95% confidence interval (CI) to consider confounding factors. Participants' age, gender, and underlying conditions were not considered during study selection. If more than one study shared the same study population, we included the study with the largest population or the longest follow-up.

Data extraction and quality assessment {#s2c}
--------------------------------------

Two experienced investigators (DS and ESL) independently examined the eligibility of all the studies extracted from the databases that met the study selection criteria. Any disagreements were resolved either via discussion or consultation with the other coauthors. The methodological quality of each of the studies was assessed by the two investigators based on the Newcastle-Ottawa Scale (NOS) \[[@R29]\]. The NOS of seven or more was considered as a good quality \[[@R30]\].

Main and subgroup analyses {#s2d}
--------------------------

In the main analysis, we investigated the association between overall use of thiazide diuretics and the risk of each type of skin cancers, including BCC, SCC, and MM. If a study did not report an aOR for overall use of thiazides, we first tried to contact authors. If there was no answer, we used that of hydrochlorothiazide (HCTZ) or HCTZ combination medications.

Subgroup meta-analyses were performed based on the types of thiazides, duration of thiazide use (long-term use), and study design (case-control or cohort study), because those factors might affect the risk of skin cancers. Use of thiazides more than 4.5 years was defined as a long-term use because included studies had used either 4.5 years or 5 years as a cut-off for long-term use. Among the various types of thiazides, we could only perform the subgroup meta-analysis on HCTZ or HCTZ combination medications due to lack of data for other types of thiazides. Similarly, the subgroup meta-analysis based on the duration of thiazide use was limited to the long-term use due to a lack of data for the short-term use. Furthermore, we could not perform subgroup analyses based on gender and individual risk factors on skin cancers, such as skin color, amount of sun exposure, or family history, due to a lack of data from the individual studies.

Statistical analyses {#s2e}
--------------------

A pooled aOR with the 95% CIs was estimated from the aORs or aRRs and their 95% CIs reported in the included studies. Since included studies were unlikely to be functionally equal and true effect size might differ between studies, we used random-effects model based on the DerSimonian-Laird method \[[@R31]\]. We assumed that the differences between the various measures of risk were not significant because the outcome of interest was sufficiently rare. Heterogeneity among the studies was evaluated using the Q-statistics (Q) with P value and Higgins I^2^ value \[[@R32]\]. Publication bias among the included studies was evaluated using the Begg's funnel plot and the Egger's test. Stata version 12.1 (StataCorp, College Station, TX, USA) was used for the statistical analysis.

Results {#s3}
=======

Identification of relevant studies {#s3a}
----------------------------------

A flow diagram of study selection is demonstrated in [Figure 1](#F1){ref-type="fig"}. A total of 4,341 articles were identified by searching three databases and manually searching relevant bibliographies. After excluding duplicate studies, we reviewed and excluded irrelevant studies based on their titles, abstracts, and full texts. In total, nine studies were included in the final analysis \[[@R17], [@R18], [@R21]-[@R27]\]. Among the studies based on the Danish Cancer Registry and Civil Registration System \[[@R18], [@R20], [@R25]\], we included a study by Schmidt et al \[[@R25]\] in the main analysis, because it was the largest study with a longer period of follow-up. In the subgroup meta-analyses, however, we used results from a study by Jensen et al \[[@R18]\], because only their study provided the required data for the subgroup analyses. Recently, Pottegard et al \[[@R27]\] published another study based on the Danish Cancer Registry. Since its study population and study period did not overlap with those of the previous Danish studies, it was independently included in our meta-analysis. Friedman et al published two studies \[[@R19], [@R22]\] using the Kaiser Permanente Medical Care Program database and a more recent study with a longer follow-up \[[@R22]\] was included in our analysis.

![Flow diagram of studies identified and selected.](jocmr-11-247-g001){#F1}

Characteristics of studies included in the analyses {#s3b}
---------------------------------------------------

The descriptive data for the studies included in the meta-analysis are summarized in [Table 1](#T1){ref-type="table"} \[[@R17], [@R18], [@R21]-[@R27]\]. We identified seven case-control studies \[[@R17], [@R18], [@R22]-[@R25], [@R27]\] and two cohort studies \[[@R21], [@R26]\]. Five studies reported data for BCC \[[@R18], [@R21], [@R23], [@R25], [@R26]\], seven studies for SCC \[[@R18], [@R22]-[@R27]\], and four studies for MM \[[@R17], [@R23], [@R25], [@R26]\]. Since SCC was a predominant type of skin cancer (97.2% of all cases) in a study by Friedman et al \[[@R22]\], their result was regarded as SCC's in this meta-analysis. Supplementary [Table 2](#T2){ref-type="table"} demonstrated the methodological quality of the studies. The NOS was seven for all studies except one \[[@R27]\] whose score was 8. The mean NOS was 7.1. Therefore, no study was excluded based on its quality.

###### Subgroup Analyses for Use of Thiazides and Risk of Skin Cancers Using Random-Effects Model

                                       No. of studies   OR (95% CI)          I^2^ (%)   Q-statistics   P value
  ------------------------------------ ---------------- -------------------- ---------- -------------- ----------
  Basal cell carcinoma                                                                                 
    Duration of use, long-term use\*   2                1.10 (0.96 - 1.25)   0.0        0.0            1.000
    Study design                                                                                       
      Case-control                     2                1.08 (0.95 - 1.23)   89.6       1.3            0.252
      Cohort                           2                1.43 (0.69 - 2.98)   96.3       26.8           \< 0.001
  Squamous cell carcinoma                                                                              
    Duration of use, long-term use\*   3                3.30 (1.85 - 5.89)   90.7       21.4           \< 0.001
    Study design                                                                                       
      Case-control                     5                1.61 (1.08 - 2.38)   92.3       52.3           \< 0.001
      Cohort                           1                NA                   NA         NA             NA
  Malignant melanoma                                                                                   
    Duration of use, long-term use\*   1                NA                   NA         NA             NA
    Study design                                                                                       
      Case-control                     3                1.13 (1.00 - 1.27)   0.0        0.6            0.761
      Cohort                           1                NA                   NA         NA             NA

I^2^: Higgins score; NA: not available. \*More than 4.5 years.

Main analysis {#s3c}
-------------

In a random-effects meta-analysis of eight observational studies comprising 395,789 participants ([Fig.2](#F2){ref-type="fig"}), we found a significant association between the use of thiazide diuretics and the risk of SCC (aOR, 1.86; 95% CI, 1.23 - 2.80; I^2^ = 93.3%; Q = 75.1, P \< 0.001). Also, there were marginally significant associations between the use of thiazides and the risk of BCC (aOR, 1.19; 95% CI, 1.02 - 1.38; I^2^ = 89.6%; Q = 28.8, P \< 0.001) and MM (aOR, 1.14; 95% CI, 1.01 - 1.29; I^2^ = 0.0%; Q = 2.5, P = 0.447).

![The risk of skin cancers among those who used thiazide diuretics. OR: odds ratio; RR: relative risk. \*Weights are from random-effects analysis.](jocmr-11-247-g002){#F2}

Subgroup meta-analysis {#s3d}
----------------------

### Types of thiazides {#s3d1}

In subgroup meta-analysis based on the types of thiazides, the use of HCTZ or HCTZ combination medications was associated with an increased risk of SCC without significant heterogeneity among studies ([Fig. 3](#F3){ref-type="fig"}; aOR, 2.04; 95% CI, 1.79 - 2.33; I^2^ = 0.0%; Q = 2.7, P = 0.445). Pooled risk of BCC or MM in HCTZ or HCTZ combination medications users was not estimated, as only one study provided such data. In addition, this subgroup meta-analysis could not be done for other types of thiazides due to a lack of data.

![Subgroup meta-analysis on the use of HCTZ or HCTZ combination medications and the risk of skin cancers. HCTZ: hydrochlorothiazide; OR: odds ratio; RR: relative risk. \*Weights are from random-effects analysis.](jocmr-11-247-g003){#F3}

### Other variables {#s3d2}

The rest of the results of subgroup meta-analyses according to the duration of use and study design are shown in [Table 2](#T2){ref-type="table"}. The long-term use of thiazides (\> 4.5 years) was significantly associated with an increased risk of SCC, but high heterogeneity was observed (aOR, 3.30; 95% CI, 1.85 - 5.89.; I^2^ = 90.7%; Q = 21.4, P \< 0.001). For BCC, there was no significant association between the long-term use of thiazides and the risk of BCC (aOR, 1.10; 95% CI, 0.96 - 1.25; I^2^ = 0.0%; Q = 0.0, P = 1.000). Not enough data for short-term thiazide users was available in the individual studies.

In the subgroup meta-analysis based on study design, there was no significant association between thiazide use and the risk of BCC. In contrast, there was only one cohort study for SCC and MM, and the overall results did not significantly change after excluding the cohort study.

Publication bias {#s3e}
----------------

Although asymmetries were observed on the funnel plots ([Fig. 4](#F4){ref-type="fig"}), Begg's adjusted rank correlation tests did not show statistical significance (P for bias = 0.279 for BCC, 0.851 for SCC, and 0.174 for MM, respectively). Also, the P values for the bias from the Egger's test were not significant (P for bias = 0.171 for BCC, 0.128 for SCC, and 0.109 for MM, respectively). However, due to small numbers of included studies, these results should be interpreted with caution and publication bias could not be fully excluded.

![Funnel plots of studies for the use of thiazide diuretics and the risk of skin cancers. (a) Basal cell carcinoma, (b) squamous cell carcinoma, and (c) malignant melanoma.](jocmr-11-247-g004){#F4}

Discussion {#s4}
==========

In this meta-analysis of observational studies, we found significant association between the use of thiazide diuretics and the risk of SCC. There were marginally significant associations between thiazide use and the risk of BCC and MM. Especially, HCTZ or HCTZ combination medications were significantly associated with an increased risk of SCC without significant heterogeneity among the studies. In a recent meta-analysis by Gandini et al \[[@R33]\], there was no significant association between thiazide diuretics and skin cancers. However, they only included six studies and pooled multiple estimates from one study that shared the same control groups. Furthermore, they did not differentiate types of skin cancers and did not perform subgroup analysis. These differences might result in the different results, and our study is by far the most updated and extensive meta-analysis on this topic.

Although the exact mechanism underlying the association between thiazides and skin cancers is unclear, the drugs' photosensitizing effect is thought to play a major role. Thiazides are sulfonamide-derived medications that can cause photosensitivity reaction \[[@R10], [@R34]-[@R36]\]. UV radiation induces dissociation of chlorine substituent of chemical structure of thiazides which causes free radical reaction and the formation of ROS \[[@R11]-[@R13]\]. These ROS induce damage to lipid membranes \[[@R37]\] and DNA \[[@R38]\]. In addition, a recent experimental study revealed that HCTZ significantly enhanced UV-A-induced DNA damage by stimulating production of thymine-thymine dimer and cyclobutane pyrimidine dimmers \[[@R39]\].Through these mechanisms, thiazide-induced photosensitivity could result in molecular and cellular damage leading to the skin cancers.

The photosensitization hypothesis is further supported by previous clinical observations of psoriasis patients treated with photochemotherapy (psoralens and UV-A (PUVA)). Several studies demonstrated that the drug-induced photosensitization of skin and subsequent exposure to UV radiation increased risk of skin cancers \[[@R14]-[@R16]\]. This increased risk was most pronounced for SCC and strongly related to the cumulative UV dose \[[@R40]\]. Our result was consistent with above findings in that the use of thiazides was most significantly associated with the risk of SCC among skin cancers. It was not surprising considering that the total sun exposure is known to be more strongly associated with SCC than other types of skin cancer \[[@R41]\]. However, further studies are required to validate this hypothesis.

In the subgroup meta-analysis based on the duration of medication use, long-term use of thiazides (\> 4.5 years) was associated with an increased risk of SCC, but not BCC. Pooled risk of SCC among the long-term thiazide users was 1.7 times as high as that of overall thiazide users (aOR, 3.30 vs. 1.86, respectively). However, the pooled risk of skin cancers in long-term thiazides users could not be directly compared to that of short-term thiazide users due to a lack of available data. Furthermore, only a few case-control studies with potential recall-bias and significant heterogeneity were included in this subgroup analysis. Therefore, an exact impact of the duration of thiazides use on the risk of skin cancers could not be determined in our study. Since one study reported significantly increased risk of SCC with increasing duration of thiazide use \[[@R22]\], future studies on this topic should consider it as a possible effect modifier.

There are several limitations in our study. First, this meta-analysis only included observational studies in the absence of randomized controlled trials on this topic. This could result in a potential for bias and unaccounted confounders. To account for this limitation, only adjusted values were used in our meta-analysis. However, the cause-and-effect relationship between the use of thiazide diuretics and skin cancers could not be determined. Second, only a few studies were available per each type of skin cancers, which limited statistical power and did not allow more extensive subgroup analysis. Third, high heterogeneity among the studies for BCC or SCC was observed in the main analysis. Difference in types of thiazides might somewhat contribute to the high heterogeneity, but it was not enough to fully explain it. However, there was no significant heterogeneity among the studies when investigating the association between the use of HCTZ or HCTZ combination medications and the risk of SCC. Fourth, the impact of individual risk factors on skin cancers, such as skin color, amount of sun exposure, or family history, could not be fully considered in our meta-analysis due to a lack of data from the individual studies. Fifth, publication bias or other small study effects are possible. Although we searched three databases that are mostly commonly used in meta-analysis, not including more databases and excluding unpublished literatures could have contributed to the publication bias.

In conclusion, our results suggest that the use of thiazide diuretics may be associated with increased risk of skin cancers. Especially, this association was pronounced between the use of HCTZ or HCTZ combination medications and the risk of SCC. Further studies are needed to confirm these findings.
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